NEUN logo

Neurogenesis, Inc. Stock Price

OTCPK:NEUN Community·US$8.2k Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

NEUN Share Price Performance

US$0.0001
0.00 (0.00%)
US$0.0001
0.00 (0.00%)
Price US$0.0001

NEUN Community Narratives

There are no narratives available yet.

Snowflake Analysis

Low risk with weak fundamentals.

3 Risks
0 Rewards

Neurogenesis, Inc. Key Details

US$1.1m

Revenue

US$217.9k

Cost of Revenue

US$851.5k

Gross Profit

US$861.1k

Other Expenses

-US$9.6k

Earnings

Last Reported Earnings
Sep 30, 2007
Next Reporting Earnings
n/a
0
0%
0%
0%
View Full Analysis

About NEUN

Founded
1984
Employees
n/a
CEO
Tal Gilat
WebsiteView website
www.neurogenesis.com

Neurogenesis, Inc. manufactures and sells nutritional supplements primarily in the United States. The company offers NeuBecalm’d, a nutritional supplement to reduce the effects of acute and chronic stress factors; NeuBecalm'd Chewables that reduces the effects of stress and enhance focus; and NeuRecover, a nutritional support for the natural replenishment of neurotransmitters depleted by the long-term use of alcohol. It also provides NeuReplenish, a nutritional support for restoring and rebuilding healthy brain chemistry that has been altered or depleted by the long-term use of chemical stimulants; NeuRelieve, a nutritional support for restoring and rebuilding healthy brain chemistry that has been altered or depleted by the long-term use of antianxiety drugs, and to be used in conjunction with professional support during the tapering process; and NeuSlim, which aids in the reduction of cravings (or urges) for simple carbohydrates, to reduce excessive appetite in general, and to assist in healthy moderation of nutritional needs. In addition, the company offers NeuBecalm'd/NeuRelieve Combo, a nutritional support for restoring and rebuilding healthy brain chemistry that has been altered or depleted by the prolonged use of prescription pain pills or from the use of opiate drugs, such as heroin or methadone, as well as used in conjunction with professional support during the tapering process. Neurogenesis, Inc. has a research collaboration with the University of Edinburgh for the development of various platform approaches to enable gene therapies. The company was founded in 1984 and is headquartered in League City, Texas.

Recent NEUN News & Updates

Recent updates

No updates